Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

NCT01623115 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

486

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Alirocumab
DRUG: Placebo (for alirocumab)
DRUG: Lipid Modifying Therapy (LMT)

Sponsor

Sanofi

Collaborators

[object Object]